Literature DB >> 28575585

Transforming growth factor-β: A therapeutic target for cancer.

Sulsal Haque1, John C Morris1,2.   

Abstract

Transforming growth factor-β (TGF-β) regulates cell growth and differentiation, apoptosis, cell motility, extracellular matrix production, angiogenesis, and cellular immunity. It has a paradoxical role in cancer. In the early stages it inhibits cellular transformation and prevents cancer progression. In later stages TGF-β plays a key role in promoting tumor progression through mainly 3 mechanisms: facilitating epithelial to mesenchymal transition, stimulating angiogenesis and inducing immunosuppression. As a result of its opposing tumor promoting and tumor suppressive abilities, TGF-β and its pathway has represented potential opportunities for drug development and several therapies targeting the TGF-β pathway have been identified. This review focuses on identifying the mechanisms through which TGF-β is involved in tumorigenesis and current therapeutics that are under development.

Entities:  

Keywords:  Antisense oligonucleotide; cancer; epithelial-mesenchymal transition; monoclonal antibody; transforming growth factor-β

Mesh：

Substances：

Year:  2017        PMID： 28575585      PMCID： PMC5557219          DOI： 10.1080/21645515.2017.1327107

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


  143 in total

1.  Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines.

Authors:  James J Kobie; Rita S Wu; Robert A Kurt; Sunming Lou; Miranda K Adelman; Luke J Whitesell; Lalitha V Ramanathapuram; Carlos L Arteaga; Emmanuel T Akporiaye
Journal:  Cancer Res       Date:  2003-04-15       Impact factor: 12.701

2.  High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene.

Authors:  Alejandra Bruna; Rachel S Darken; Federico Rojo; Alberto Ocaña; Silvia Peñuelas; Alexandra Arias; Raquel Paris; Avelina Tortosa; Jaume Mora; Jose Baselga; Joan Seoane
Journal:  Cancer Cell       Date:  2007-02       Impact factor: 31.743

3.  Expression of ALK-1, a type 1 serine/threonine kinase receptor, coincides with sites of vasculogenesis and angiogenesis in early mouse development.

Authors:  B A Roelen; M A van Rooijen; C L Mummery
Journal:  Dev Dyn       Date:  1997-08       Impact factor: 3.780

4.  A deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation by transforming growth factor beta in a cutaneous T-cell lymphoma.

Authors:  W P Schiemann; W M Pfeifer; E Levi; M E Kadin; H F Lodish
Journal:  Blood       Date:  1999-10-15       Impact factor: 22.113

5.  Proliferation and Cdk4 expression in microsatellite unstable colon cancers with TGFBR2 mutations.

Authors:  William M Grady; Joseph E Willis; Patty Trobridge; Judith Romero-Gallo; Nina Munoz; Joseph Olechnowicz; Kelly Ferguson; Shiva Gautam; Sanford D Markowitz
Journal:  Int J Cancer       Date:  2006-02-01       Impact factor: 7.396

6.  Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients.

Authors:  J Nemunaitis; M Nemunaitis; N Senzer; P Snitz; C Bedell; P Kumar; B Pappen; P B Maples; D Shawler; H Fakhrai
Journal:  Cancer Gene Ther       Date:  2009-03-13       Impact factor: 5.987

7.  Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells.

Authors:  P A Ruffini; L Rivoltini; A Silvani; A Boiardi; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1993-06       Impact factor: 6.968

8.  Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor.

Authors:  D R Edwards; G Murphy; J J Reynolds; S E Whitham; A J Docherty; P Angel; J K Heath
Journal:  EMBO J       Date:  1987-07       Impact factor: 11.598

9.  Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts.

Authors:  Armin Maier; Anne-Lise Peille; Vincent Vuaroqueaux; Michael Lahn
Journal:  Cell Oncol (Dordr)       Date:  2015-01-09       Impact factor: 6.730

10.  Transforming growth factor β neutralization ameliorates pre-existing hepatic fibrosis and reduces cholangiocarcinoma in thioacetamide-treated rats.

Authors:  Hong Ling; Eric Roux; Donna Hempel; Jingzang Tao; Mandy Smith; Scott Lonning; Anna Zuk; Cynthia Arbeeny; Steve Ledbetter
Journal:  PLoS One       Date:  2013-01-17       Impact factor: 3.240
View more
  69 in total

Review 1.  The interplay between cancer associated fibroblasts and immune cells in the context of radiation therapy.

Authors:  Miles Piper; Adam C Mueller; Sana D Karam
Journal:  Mol Carcinog       Date:  2020-05-04       Impact factor: 4.784

2.  Identification and validation of xenobiotic metabolism-associated prognostic signature based on five genes to evaluate immune microenvironment in colon cancer.

Authors:  Lina Wen; Zongqiang Han
Journal:  J Gastrointest Oncol       Date:  2021-12

3.  Negative trade-off between neoantigen repertoire breadth and the specificity of HLA-I molecules shapes antitumor immunity.

Authors:  Máté Manczinger; Balázs Koncz; Gergő Mihály Balogh; Benjamin Tamás Papp; Leó Asztalos; Lajos Kemény; Balázs Papp; Csaba Pál
Journal:  Nat Cancer       Date:  2021-07-08

Review 4.  Molecular study of the proliferation process of beta cells derived from pluripotent stem cells.

Authors:  Saeedeh Akhavan; Sara Tutunchi; Ali Malmir; Parisa Ajorlou; Arsalan Jalili; Ghodratollah Panahi
Journal:  Mol Biol Rep       Date:  2021-11-03       Impact factor: 2.316

5.  The anti-tumour effect of induced pluripotent stem cells against submandibular gland carcinoma in rats is achieved via modulation of the apoptotic response and the expression of Sirt-1, TGF-β, and MALAT-1 in cancer cells.

Authors:  Eman Mohamed Faruk; Dina Sabry; Ahmed A Morsi; Yasmine Alaa El-Din; Neama M Taha; Engy Medhat
Journal:  Mol Cell Biochem       Date:  2021-09-17       Impact factor: 3.396

Review 6.  Cytokine storm and targeted therapy in hemophagocytic lymphohistiocytosis.

Authors:  Han-Qi Zhang; Si-Wei Yang; Yi-Cheng Fu; Ming-Cong Chen; Cheng-Hao Yang; Ming-Hua Yang; Xiao-Dan Liu; Qing-Nan He; Hua Jiang; Ming-Yi Zhao
Journal:  Immunol Res       Date:  2022-07-11       Impact factor: 4.505

7.  Induction of ADAM10 by Radiation Therapy Drives Fibrosis, Resistance, and Epithelial-to-Mesenchyal Transition in Pancreatic Cancer.

Authors:  Adam C Mueller; Miles Piper; Andrew Goodspeed; Shiv Bhuvane; Jason S Williams; Shilpa Bhatia; Andy V Phan; Benjamin Van Court; Kathryn L Zolman; Brisa Peña; Ayman J Oweida; Sara Zakem; Cheryl Meguid; Michael W Knitz; Laurel Darragh; Thomas E Bickett; Jacob Gadwa; Luisa Mestroni; Matthew R G Taylor; Kimberly R Jordan; Peter Dempsey; M Scott Lucia; Martin D McCarter; Marco Del Chiaro; Wells A Messersmith; Richard D Schulick; Karyn A Goodman; Michael J Gough; Casey S Greene; James C Costello; Antonio Galveo Neto; David Lagares; Kirk C Hansen; Adrie Van Bokhoven; Sana D Karam
Journal:  Cancer Res       Date:  2021-02-01       Impact factor: 12.701

8.  Activation of the DDR Pathway Leads to the Down-Regulation of the TGFβ Pathway and a Better Response to ICIs in Patients With Metastatic Urothelial Carcinoma.

Authors:  Chaozheng Zhou; Anqi Lin; Manming Cao; Weimin Ding; Weiming Mou; Ningyi Guo; Zhenyu Chen; Jian Zhang; Peng Luo
Journal:  Front Immunol       Date:  2021-06-18       Impact factor: 7.561

9.  Angiotensin-II activates vascular inflammasome and induces vascular damage.

Authors:  Stefany B Cau; Ariane Bruder-Nascimento; Marcondes B Silva; Fernanda N Z Ramalho; Fabiola Mestriner; Rheure Alves-Lopes; Nathanne Ferreira; Rita C Tostes; Thiago Bruder-Nascimento
Journal:  Vascul Pharmacol       Date:  2021-06-09       Impact factor: 5.738

10.  Screening and Validation of the Hypoxia-Related Signature of Evaluating Tumor Immune Microenvironment and Predicting Prognosis in Gastric Cancer.

Authors:  Jun-Peng Pei; Chun-Dong Zhang; Maimaititusun Yusupu; Cheng Zhang; Dong-Qiu Dai
Journal:  Front Immunol       Date:  2021-06-25       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.